Stay updated with breaking news from Nasdaq swtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a report released on Thursday, RTT News reports. They presently have a $75.00 price objective on the stock, up from their previous price objective of $70.00. Wedbush’s price target indicates a potential upside of 66.26% from […] ....
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw unusually-high trading volume on Thursday . Approximately 759,786 shares traded hands during mid-day trading, a decline of 30% from the previous session’s volume of 1,085,049 shares.The stock last traded at $42.19 and had previously closed at $46.84. Analyst Ratings Changes A number of equities research analysts […] ....
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) is set to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect SpringWorks Therapeutics to post earnings of ($1.19) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. SpringWorks Therapeutics (NASDAQ:SWTX […] ....
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) – Analysts at Wedbush raised their Q1 2024 EPS estimates for SpringWorks Therapeutics in a research report issued to clients and investors on Tuesday, February 27th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.27) per share for the quarter, up from their […] ....
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.20), Briefing.com reports. The company had revenue of $5.45 million during the quarter, compared to the consensus estimate of $1.26 million. During the same period in […] ....